These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 27298504)

  • 41. Lack of Association between 5α-Reductase Inhibitors and Depression.
    Dyson TE; Cantrell MA; Lund BC
    J Urol; 2020 Oct; 204(4):793-798. PubMed ID: 32294395
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Post-finasteride syndrome - does it really exist?
    Maksym RB; Kajdy A; Rabijewski M
    Aging Male; 2019 Dec; 22(4):250-259. PubMed ID: 30651009
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A 5-year retrospective analysis of 5α-reductase inhibitors in men with benign prostatic hyperplasia: finasteride has comparable urinary symptom efficacy and prostate volume reduction, but less sexual side effects and breast complications than dutasteride.
    Kaplan SA; Chung DE; Lee RK; Scofield S; Te AE
    Int J Clin Pract; 2012 Nov; 66(11):1052-5. PubMed ID: 23067029
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Association between 5-alpha reductase inhibition and risk of hip fracture.
    Jacobsen SJ; Cheetham TC; Haque R; Shi JM; Loo RK
    JAMA; 2008 Oct; 300(14):1660-4. PubMed ID: 18840839
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Sexual dysfunction with 5-alpha-reductase inhibitor therapy for androgenetic alopecia: A global propensity score matched retrospective cohort study.
    Lauck KC; Limmer A; Harris P; Kivelevitch D
    J Am Acad Dermatol; 2024 Jul; 91(1):163-166. PubMed ID: 38552905
    [No Abstract]   [Full Text] [Related]  

  • 46. Reversible myopathy and ophthalmoparesis after low-dose finasteride administration for androgenic alopecia.
    Ryu HJ; Kwon DY
    Dermatol Surg; 2014 May; 40(5):595-7. PubMed ID: 24533595
    [No Abstract]   [Full Text] [Related]  

  • 47. 5α-Reductase inhibitors in men aged 50 years or older with androgenetic alopecia: A retrospective study.
    Kang MJ; Choi JY; Sim WY; Lew BL
    J Am Acad Dermatol; 2021 Jan; 84(1):172-173. PubMed ID: 32320771
    [No Abstract]   [Full Text] [Related]  

  • 48. Therapeutic hotline. Treatment of androgenic alopecia with finasteride may result in a high grade prostate cancer in patients: fact or fiction?
    Lynn R; Krunic A
    Dermatol Ther; 2010; 23(5):544-6. PubMed ID: 20868409
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Topical finasteride for the treatment of male androgenetic alopecia and female pattern hair loss: a review of the current literature.
    Suchonwanit P; Iamsumang W; Leerunyakul K
    J Dermatolog Treat; 2022 Mar; 33(2):643-648. PubMed ID: 32538225
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Finasteride adverse effects: An update].
    Carreño-Orellana N; Moll-Manzur C; Carrasco-Zuber JE; Álvarez-Véliz S; Berroeta-Mauriziano D; Porras-Kusmanic N
    Rev Med Chil; 2016 Dec; 144(12):1584-1590. PubMed ID: 28393993
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Male breast cancer and 5α-reductase inhibitors finasteride and dutasteride.
    Bird ST; Brophy JM; Hartzema AG; Delaney JA; Etminan M
    J Urol; 2013 Nov; 190(5):1811-4. PubMed ID: 23665270
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Differences in reproductive toxicology between alopecia drugs: an analysis on adverse events among female and male cases.
    Wu M; Yu Q; Li Q
    Oncotarget; 2016 Dec; 7(50):82074-82084. PubMed ID: 27738338
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Adverse side effects of 5α-reductase inhibitors therapy: persistent diminished libido and erectile dysfunction and depression in a subset of patients.
    Traish AM; Hassani J; Guay AT; Zitzmann M; Hansen ML
    J Sex Med; 2011 Mar; 8(3):872-84. PubMed ID: 21176115
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Specific antigen prostatic changes during treatment with finasteride or dutasteride for benign prostatic hyperplasia].
    Arena F
    Minerva Urol Nefrol; 2013 Sep; 65(3):211-6. PubMed ID: 23872632
    [TBL] [Abstract][Full Text] [Related]  

  • 55. 5-Alpha reductase inhibitor related litigation: A legal database review.
    Low P; Li KD; Hakam N; Bell A; Abbasi B; Lui J; Shaw NM; Breyer BN
    Andrology; 2022 Mar; 10(3):470-476. PubMed ID: 34933409
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS).
    Nickel JC; Gilling P; Tammela TL; Morrill B; Wilson TH; Rittmaster RS
    BJU Int; 2011 Aug; 108(3):388-94. PubMed ID: 21631695
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The efficacy and safety of dutasteride compared with finasteride in treating men with androgenetic alopecia: a systematic review and meta-analysis.
    Zhou Z; Song S; Gao Z; Wu J; Ma J; Cui Y
    Clin Interv Aging; 2019; 14():399-406. PubMed ID: 30863034
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Finasteride associated melasma in a Caucasian male.
    Famenini S; Gharavi NM; Beynet DP
    J Drugs Dermatol; 2014 Apr; 13(4):484-6. PubMed ID: 24719069
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Are hand preference and sexual orientation possible predicting factors for finasteride adverse effects in male androgenic alopecia?
    Motofei IG; Rowland DL; Georgescu SR; Tampa M; Baleanu BC; Paunica S
    Exp Dermatol; 2016 Jul; 25(7):557-8. PubMed ID: 26990657
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Effect of dutasteride on reduction of plasma DHT following finasteride therapy in patients with benign prostatic hyperplasia].
    Botto H; Lan O; Poulain JE; Comenducci A
    Prog Urol; 2005 Dec; 15(6):1090-5. PubMed ID: 16429658
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.